bearish
Standing Alone in the Ampakines Pipeline: Biogen Sees Potential in Pfizer's Neuropsychiatry Asset
197 Views15 Mar 2018 22:36
On 12 March 2018, Biogen Inc (BIIB US) announced an agreement to acquire Pfizer Inc (PFE US)'s first-in-class, Phase 2b ready AMPA receptor...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Winnie Wong
Healthcare Specialist
Price Chart(Sign Up to Access)
- Standing Alone in the Ampakines Pipeline: Biogen Sees Potential in Pfizer's Neuropsychiatry Asset15 Mar 2018
- Will Actinogen Ace Alzheimer's?01 Mar 2018
- Acadia Pharma: Hedge Fund Favorite and Upcoming Catalyst.09 Dec 2016
- Some Actionable Ideas in the Biotechnology and Pharmaceutical Sector: October 31 Sector Update01 Nov 2016
x